Groww Logo
Home>US Stocks>Incyte Corporation

Incyte Corporation

Healthcare
$75.11
- $1.80 (2.34%) 1D
1D
1W
1M
1Y
3Y
5Y

Performance

Today’s Low
$
    Today’s High
    $
    52W Low
    $
      52W High
      $
      Open PricePrev. CloseVolumeAvg. Volume
      $76.66$75.11711,437,476

      Fundamentals

      Market Cap$16.63B
      P/B Ratio4.3
      P/E Ratio17.8
      Enterprise Value$14.41B
      Div. Yield0.00%
      Book Value17.45
      EPS(TTM)0.17
      ROENA
      Understand Fundamentals

      About the Company

      Incyte Corp is a Wilmington, Delaware based biopharmaceutical company with an extensive global presence. With approximately 1,500 employees, the company has operations in the United States, Japan and Europe. With expertise in medicinal chemistry and
      Incyte Corp is a Wilmington, Delaware based biopharmaceutical company with an extensive global presence. With approximately 1,500 employees, the company has operations in the United States, Japan and Europe. With expertise in medicinal chemistry and biology, Incyte develops products, helmed by world-class scientists. The company produces medicines under two franchises - Inflammation & Autoimmunity and Oncology. However, it develops medicines for four therapeutic areas, namely Immunology, Oncology, Rheumatology and Dermatology. As of 2020, it has 19 molecular targets and 22 clinical candidates it is working upon. Some of its medicines are Jakafi, INCB00928, INCB86550, Pemigatinib, Iclusig, Pemazyre, Monjuvi, Tabrecta, Olumiant, etc. The molecules it is developing for its drugs include FGFR, JAK, ARG, GITR, LAG-3, PI3Kδ, PD-1/PD-L1, TIM-3, etc. Between 2009 and 2020, Incyte has collaborated with ten companies, producing medicines like capmatinib20, Tabrecta, baricitinib17 and Olumiant. Few of the notable companies it has partnered with are Eli Lilly and Company, Agenus Inc., MacroGenics Inc., MorphoSys AG, Novartis International Pharmaceutical Ltd., Zai Lab, Ltd., Merus N.V., Innovent Biologics, Inc., ARIAD Pharmaceuticals, Inc. and Calithera Biosciences, Inc. Incyte was formed in 2002 by a group of scientists, biologists and chemists who were working in immunology. As of 2020, it is an S&P 500 component as well as a NASDAQ 100 component. It trades in the NASDAQ stock exchange under the ticker symbol INCY. It holds the 953rd rank in the 2020 Fortune 1000 list of companies. In the same year, it made into the Forbes list of Global 2000 companies. In 2018, it was the 7th most innovative company in the world, according to Forbes rankings.
      ...Read more
      OrganisationIncyte Corporation
      IndustryBiotechnology
      HeadQuartersWilmington, DE

      Company Financials

      *All values are in Million $
      No Graph Data To Display
      Quarterly
      Yearly
      See Details

      FAQs on Incyte Corporation

      Can I Buy Incyte Corporation Shares in India?

      Yes, Incyte Corporation shares can be bought in India by opening an international trading account with Groww.

      How to Buy Incyte Corporation Shares in India?

      One can easily invest in Incyte Corporation shares from India by: Direct Investment - Opening an international trading account with Groww which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Incyte Corporation shares. Indirect Investment - Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Incyte Corporation.

      What is the Share Price of Incyte Corporation?

      The share price of Incyte Corporation is in Dollars and if you are investing from India, you can always check the INR valuation before investing. The current Incyte Corporation share price is $75.11 as of 25 May ‘22

      What is the Market Cap of Incyte Corporation?

      The Incyte Corporation market cap is $16.63B as of 25 May ‘22

      What is the PE and PB ratio of Incyte Corporation?

      The PE and PB ratio of Incyte Corporation is 17.8 and 4.3 as of 25 May ‘22
      ⓒ 2016-2022 Groww. All rights reserved, Built with in India
      MOST POPULAR ON GROWWVERSION - 2.4.0
      STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
      MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI

      ABOUT GROWW